Sarepta Therapeutics (SRPT) Stock Price, Quote & News

Company Profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dy...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 274 4000

Website: www.sarepta.com

Address:

215 First Street, Suite 415, Cambridge, United States

iCro93 Aug. 23 at 5:51 PM

$SRPT can you name ONE (1) drug on this planet , without ANY side effects ? Where you would put your life on the line to say; „Yes, 100% safe take this“. ?

0 · Reply

BarryMCner Aug. 23 at 5:36 PM

$SRPT I hope soo too, but I'm a little bit concerned. Below is why SRPT's 2027 convertible notes were at 1.25% interest, convertible to equity at ~$142/share. They refinance 700MM of these notes into 602MM of new higher interest (4.875%) notes convertible to stock at a lower ($60/share) price. In summary, interest just quadrupled, share price conversion price was halved, for what upside? Interested in hearing everyone's thoughts.

1 · Reply

TheSteveSmiths1 Aug. 23 at 5:17 PM

$SRPT My hope (based on nothing more than speculation) is that SRPT was raising cash to first refinance debt so that it can next restart its stock repurchased program. He probably thinks his companies stock is a very good investment right now. I agree!

0 · Reply

StonkMessiah Aug. 23 at 5:16 PM

$SRPT I’m seriously beginning to wonder what the shares outstanding and float currently is and will be at 3Q end. After reading all these posts including the one below, if the company has significantly reduced its small outstanding share base of 98M when the stock was at $10.41 on 07/24 to now up to $22 in coming days after the convertible debt deal, the shares outstanding could be significantly down and the convertible debt shares maybe already be repurchased or soon to be plus more. Coupled with more institutional buying while short interest is sky high, we may have what we call a situation here. Time will tell.

1 · Reply

MarketPro Aug. 23 at 4:49 PM

$SRPT 💸 Cost Reduction Measures Sarepta initiated a strategic restructuring in July 2025, which includes: • 36% workforce reduction (~500 employees) •$120M in annual cash savings from headcount cuts starting in 2026 Total expected cost savings: $400M annually, primarily from: • Reduced R&D and SG&A expenses. • Pipeline reprioritization (focus on siRNA, pause on LGMD gene therapies) Adjusted manufacturing commitments based on demand Q2 2025 Actuals: • Adjusted EPS: $2.02 (vs. $0.43 in Q2 2024) • Revenue: $611.1M (+68% YoY) • Operating profit: Positive GAAP and non-GAAP

0 · Reply

MarketPro Aug. 23 at 4:37 PM

$SRPT Top Holders by Market Value. Note GREEN Arrows to the right showing INCREASED buying..... They don't seem to be scared off to me....

0 · Reply

Initiator1 Aug. 23 at 4:06 PM

$SRPT This is a $100+ stock any day. Soon it’ll reclaim its lost glory.

0 · Reply

WBinthehouse Aug. 23 at 3:53 PM

$SRPT yah but after SRPTs huge expenses to run the business both Elevydys and PMO GAPP in million single digits. Lol

1 · Reply

Gladiator007 Aug. 23 at 3:47 PM

$SRPT I see you estimated Elevidys revenue to be at 188M for the next quarter. So the total revenue with other drugs can be at the least between 440 - 460 Million. Annual revenue projection with these figures will still be between 1.8 Billion to 2 Billion Dollars It is still trading at 1x of it's annual revenue. Don't you think it is Way undervalued?

1 · Reply

Gladiator007 Aug. 23 at 3:28 PM

$SRPT As per your assessment, Elevidys revenue for the quarter is not more than 30 Milion? Down from 380 Million the previous quarter to 30 Million? Can you explain?

1 · Reply

SRPT CLASS REMINDER: Suffer Losses on Your Sarepta Therapeutics, Inc. Investment? Contact BFA Law before the August 25 Court Deadline (NASDAQ:SRPT)

Aug 22, 2025, 12:12 PM EDT - 1 day ago

Sarepta Therapeutics: A Strong Opportunity Amidst The Panic

Aug 22, 2025, 9:50 AM EDT - 1 day ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

Aug 21, 2025, 7:00 AM EDT - 2 days ago

Sarepta Therapeutics Announces Refinancing of Approximately $700 Million of 1.25% Convertible Senior Notes due 2027

Aug 21, 2025, 3:54 AM EDT - 2 days ago

SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT

Aug 20, 2025, 3:30 PM EDT - 2 days ago

SRPT Update: Hagens Berman Urges Sarepta Investors to Act Before August 25 Deadline

Aug 18, 2025, 12:01 PM EDT - 5 days ago

Sarepta Therapeutics (SRPT) August 25, 2025 Lead Plaintiff Deadline Approaching, SRPT Investors with Substantial Losses Encouraged to Contact Hagens Berman

Aug 14, 2025, 12:14 PM EDT - 9 days ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

Aug 13, 2025, 4:12 PM EDT - 9 days ago

Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment

Aug 13, 2025, 8:33 AM EDT - 10 days ago

SAREPTA STOCK: Lose Money on Your Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Investment? Contact BFA Law before the August 25 Legal Deadline

Aug 11, 2025, 8:18 AM EDT - 12 days ago

SRPT COURT NOTICE: Sarepta Therapeutics Investors may have been Affected by Fraud -- Contact BFA Law before August 25 if You Suffered Losses (NASDAQ:SRPT)

Aug 11, 2025, 5:26 AM EDT - 12 days ago

These Stocks Are Moving the Most Today: Coinbase, MicroStrategy, Sarepta, Nvidia, AMD, and More

AMD COIN MSTR NVDA

Aug 6, 2025, 4:05 PM EDT - 16 days ago

Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate Developments

Jul 31, 2025, 8:48 AM EDT - 23 days ago

Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results

Jul 31, 2025, 8:45 AM EDT - 23 days ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of August 25, 2025 in Sarepta Therapeutics, Inc. Lawsuit - SRPT

Jul 30, 2025, 11:07 AM EDT - 24 days ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

CAPR CABA NGNE NTLA QURE RCKT

Jul 30, 2025, 8:36 AM EDT - 24 days ago

SRPT INVESTORS: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Investors may have been Affected by Fraud – Contact BFA Law by August 25 about Potentially Recovering Losses

Jul 29, 2025, 5:48 PM EDT - 24 days ago

Opinion | On Sarepta, a Welcome FDA Reversal

Jul 29, 2025, 2:47 PM EDT - 24 days ago

Sarepta finally gets some good news: A patient death wasn't its DMD drug's fault.

Jul 29, 2025, 2:06 PM EDT - 24 days ago

SRPT Rallies on FDA Green Light: A New Bottom for the Stock?

Jul 29, 2025, 1:27 PM EDT - 25 days ago

FDA Lifts Safety Hold On Sarepta's Muscular Dystrophy Gene Therapy—Wall Street Cheers

Jul 29, 2025, 10:40 AM EDT - 25 days ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics

Jul 29, 2025, 9:00 AM EDT - 25 days ago

Sarepta: SRPT Stock To $40?

Jul 29, 2025, 8:38 AM EDT - 25 days ago

Sarepta shares soar 36% after FDA clears partial resumption of Elevidys shipments

Jul 29, 2025, 7:21 AM EDT - 25 days ago

Sarepta shares rebound after shipments of gene therapy Elevidys resume in US

Jul 29, 2025, 7:01 AM EDT - 25 days ago

Sarepta resumes shipping of gene therapy Elevidys to patients who can walk

Jul 29, 2025, 5:01 AM EDT - 25 days ago

Sarepta Stock Just Soared 45%. Here's Why.

Jul 28, 2025, 5:09 PM EDT - 25 days ago

FDA Informs Sarepta That It Recommends That Sarepta Remove Its Pause and Resume Shipments of ELEVIDYS for Ambulatory Individuals With Duchenne Muscular Dystrophy

Jul 28, 2025, 4:59 PM EDT - 25 days ago

US FDA recommends removal of hold on Sarepta's Elevidys in some patients

Jul 28, 2025, 8:36 AM EDT - 26 days ago

SRPT LAWSUIT: Sarepta Therapeutics, Inc. Sued for Fraud after Patient Deaths – Contact BFA Law by August 25 Court Deadline (NASDAQ:SRPT)

Jul 28, 2025, 7:30 AM EDT - 26 days ago

Arrowhead Pharmaceuticals Earns $100 Million Milestone from Sarepta Therapeutics

ARWR

Jul 28, 2025, 5:46 AM EDT - 26 days ago

Sarepta Stock Drops After Downgrade and FDA Probe. The Crisis Explained.

Jul 28, 2025, 4:17 AM EDT - 26 days ago

Sarepta Therapeutics: Beaten Down, But Not Out

Jul 27, 2025, 1:37 PM EDT - 27 days ago

Opinion | The Sarepta Mugging and Drug Innovation

Jul 25, 2025, 7:51 PM EDT - 4 weeks ago

Sarepta Therapeutics Provides Clarifying Statement on ELEVIDYS

Jul 25, 2025, 5:54 PM EDT - 4 weeks ago

US FDA investigates third death after treatment with Sarepta's gene therapy Elevidys

Jul 25, 2025, 11:09 AM EDT - 4 weeks ago

Sarepta Gets Thumbs Down From Regulators Regarding Elevidys Gene Therapy

Jul 25, 2025, 8:34 AM EDT - 4 weeks ago

Sarepta Therapeutics Acknowledges CHMP Negative Opinion for ELEVIDYS in the European Union

Jul 25, 2025, 8:10 AM EDT - 4 weeks ago

Goldman Sachs' Salveen Richter on Sarepta's ongoing troubles, opportunities in biotech

Jul 25, 2025, 7:13 AM EDT - 4 weeks ago

EU regulator does not recommend approval of Sarepta's muscle disorder gene therapy

Jul 24, 2025, 8:06 AM EDT - 4 weeks ago

SRPT STOCK NEWS: Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is Facing Securities Fraud Allegations – Investors with Losses are Notified to Contact BFA Law by August 25 Deadline

Jul 23, 2025, 12:10 PM EDT - 4 weeks ago

InnovationRx: Sarepta Blinks In Showdown With FDA

Jul 23, 2025, 8:05 AM EDT - 4 weeks ago

Sarepta's licensing patner Arrowhead expects near-term payments despite setbacks

Jul 22, 2025, 1:30 PM EDT - 4 weeks ago

How The Negative Developments At Sarepta Therapeutics Impact Arrowhead Pharmaceuticals

ARWR

iCro93 Aug. 23 at 5:51 PM

$SRPT can you name ONE (1) drug on this planet , without ANY side effects ? Where you would put your life on the line to say; „Yes, 100% safe take this“. ?

0 · Reply

BarryMCner Aug. 23 at 5:36 PM

1 · Reply

TheSteveSmiths1 Aug. 23 at 5:17 PM

0 · Reply

StonkMessiah Aug. 23 at 5:16 PM

1 · Reply

MarketPro Aug. 23 at 4:49 PM

0 · Reply

MarketPro Aug. 23 at 4:37 PM

$SRPT Top Holders by Market Value. Note GREEN Arrows to the right showing INCREASED buying..... They don't seem to be scared off to me....

0 · Reply

Initiator1 Aug. 23 at 4:06 PM

$SRPT This is a $100+ stock any day. Soon it’ll reclaim its lost glory.

0 · Reply

WBinthehouse Aug. 23 at 3:53 PM

$SRPT yah but after SRPTs huge expenses to run the business both Elevydys and PMO GAPP in million single digits. Lol

1 · Reply

Gladiator007 Aug. 23 at 3:47 PM

1 · Reply

Gladiator007 Aug. 23 at 3:28 PM

$SRPT As per your assessment, Elevidys revenue for the quarter is not more than 30 Milion? Down from 380 Million the previous quarter to 30 Million? Can you explain?

1 · Reply

John62 Aug. 23 at 3:22 PM

$CAPR This is precisely what happened to him and why he is salty on SRPT . CAPR is down over 30 pct since then and SRPT is up 50 pct . So take his extremely biased views with a large grain of salt $SRPT . Poor guy

1 · Reply

BuyNHold4riches Aug. 23 at 3:00 PM

$SRPT this will consolidate one more week around $19-$21 and will take off to $25-$28 starting after Labor Day.

1 · Reply

WBinthehouse Aug. 23 at 3:00 PM

$SRPT Sarepta Therapeutics reported a net income of $196.9 million for the second quarter of 2025. Using 2Q25 as guide into the future AND taking away Japan one time milestone and non ambulant patients that are currently on hold of $188 million, The estimated reported NET REVENUE falls to $8.9 million. That’s why Doug is hoarding cash selling ARWR stocks for a loss and extending debt payment out, paying mucho high interest rates because cash is a problem. That’s the FACT Jack. Prove me wrong.

1 · Reply

WBinthehouse Aug. 23 at 2:44 PM

$SRPT @SwissBull7 Alliw me give you some context in the 2Q earnings. Let me break it down. -Net product revenue: $281.9 million -Milestone payment: $63.5M Japan regulatory approval . One time only. -Roche Royalty revenues: $5.1M -Contract manufacturing revenues: $27 million Total Elevidys-related revenue: $377.5 million Here is where it looks iffy looking ahead in the future; Subtract $63.5M for the Japan milestone payment which us a one time add on, the difference total is $314M. Now you take that $314M and you subtract 40% of non ambulatory patients, which is the projected market share according to smart people, that is now FDA haulted as of today, that leaves SRPT estimate using 2Q25 as guide into the future grand total of $188M rev. The future of Elevidys including the controversies as we speak don’t look too hot! THATS THE FACT JACK!! Got that lol

2 · Reply

The_Scientist Aug. 23 at 2:33 PM

$SRPT seeing the 🪳 🪳 who spread panic and fear here everyday are now discussing science 🧬 🧬 lol 🤣. Please stop embarrassing yourselves. Go back to sewer and have a great weekend.

0 · Reply

BuyNHold4riches Aug. 23 at 2:27 PM

$SRPT this was 2 days ago. I think this dude got shaken out yesterday and now he’s posting all negative shit. Flip flopper to the max.

2 · Reply

Stoogie Aug. 23 at 2:27 PM

$SRPT what’s the odds of this going above $22 next week?

2 · Reply

WBinthehouse Aug. 23 at 2:20 PM

$SRPT you’re right Elevidys is a one shot deal and if something better comes up the kids are not eligible. Elevidys claim to fame is in its confirmatory trial it did not do better than placebo, therefore its clinical benefit is not statistically significant. Don’t rile at me, look it up you’ll see it in black and white. You’ll see other write ups that it could be. But if the clinical trial judges said it’s not and some will come and say it is, then you have a controversial situation. I’ll go with the FDA clinical trial.

1 · Reply

JDRichie Aug. 23 at 1:45 PM

$SRPT Friday 08.22.25, there were 31 block trades on level 2 which totaled approximately 1.414 million shares. Of this total 1.335 million were buys and 79 thousand were sells, That is approximately 95% of block purchases BUYING!

1 · Reply

twin_dad Aug. 23 at 1:16 PM

$SRPT something isn’t right here, I think something really bad happened here. Could it be what we are seeing is Wall Street coming together to right the ship! AAV gene therapy is a one and done thing. Believe it or not big pharma doesn’t want a one and done treatment. Especially when there’s better treatments out on the horizon. My humble opinion is we must provide treatment now. Because as Sarepta has stated time is muscle!

1 · Reply

SwissBull7 Aug. 23 at 12:38 PM

$SRPT Worst Case Outlook – Start 2026 Min. Revenue $1.4B (PMO $900M / Elividys $500M – minimum 200 US patients) Max. Expenses $900M Min. Net Income $500M Max. Shares Outstanding 110M EPS $4.55 PE 10 (very low) Valuation $5.5B My lowest possible calculation Implied Share Price $45.45 Still believe they quietly buy back at least $250M worth of shares this Q and only show it in Q3 report. This will fuel a sharp rerating in Q3 🚀

3 · Reply

WBinthehouse Aug. 23 at 12:18 PM

$SRPT lol… you know the company diluted shareholders from the refi by ~ 8.1 million shares, 6.7 million from the exchange and 1.4 million from the private placement. The OS climbed to 105.8 million from 97.7 million, an 8.3% rise from the previous outstanding share count. Principal amount $602M, interest rate grew to 4.875% from 1.25%. Annual interest to be paid = $29.3M compared $8.8 M from the old loan. HUGE! This new deal kicks the can further down the road. The company knows it cant meet their $600 million payment due in 16 months. It’s evident cash is a problem, SRPT raising cash taking a $100M loss from the ARWR asset is fact! So you want a buyback from the 8.1 million shares just added to the previous outstanding shares lol. Great right because this will raise cash concerns and the company will have to dilute, sell more assets for a loss and layoff more workers. Doug is not that stupid to place SRPT situation a lot worse or maybe he is based on recent goofs. Good luck!

2 · Reply

Market Cap	1.96B
Revenue (ttm)	1.90B
Net Income (ttm)	235.24M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	12.37%
Debt to Equity Ratio	0.84

Volume	9,540,199
Avg Vol	14,234,352
Day's Range	N/A - N/A
Shares Out	97.71M
Stochastic %K	58%
Beta	0.46
Analysts	Sell
Price Target	$23.38